Navigation Links
Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Date:10/5/2007

COLLEGEVILLE, Pa., Oct. 5 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), presented new data today from two Phase 3 studies, which showed that bazedoxifene/conjugated estrogens reduced the number and severity of hot flashes in symptomatic postmenopausal women by up to 80 percent, when compared with placebo. These data, presented at the North American Menopause Society Annual Meeting, also showed that bazedoxifene/conjugated estrogens improved symptoms of vulvar and vaginal atrophy. In addition, secondary data from both studies showed that when compared with placebo, bazedoxifene/conjugated estrogens reduced sleep disturbances and improved menopause-related quality of life.

"The pairing of bazedoxifene, a selective estrogen receptor modulator, or SERM, with conjugated estrogens may lead to a new class of menopausal therapy called tissue selective estrogen complex, or TSEC," says Ginger Constantine, M.D., Vice President, Women's Health Care and Bone Repair, Wyeth Pharmaceuticals. "TSECs pair the benefits of estrogens with SERMs to create a distinct clinical profile, which may provide relief of hot flashes and vaginal dryness as well as bone and uterine protection."

Update on NDA Filing

Wyeth plans to submit its New Drug Application (NDA) to the U.S. Food and Drug Administration for bazedoxifene/conjugated estrogens in the second quarter of 2008 subject to the further analysis and successful completion of product formulation, bioequivalence and clinical studies, and other remaining work necessary to finalize the NDA.

Significant Reduction of Hot Flashes and Relief of Vulvar and Vaginal Atrophy Symptoms

Results of a clinical trial titled "A Phase 3 Study of th
'/>"/>

SOURCE Wyeth
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Wyeth Presents Phase 3 Data for Pristiq, an Investigational Non-Hormonal Therapy for Menopausal Hot Flashes and Night Sweats
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)...  TNI BioTech, Inc. (OTCQB: TNIB) ("TNIB" or ... development, marketing and distribution of opioid-related immunotherapies, announced ... with the Securities and Exchange Commission in connection ... be held on Thursday, September 4, 2014, at ... for determining those shareholders eligible to receive notice ...
(Date:7/28/2014)... , July 28, 2014 Concord Medical Services ... CCM ), a leading specialty hospital management solution ... and diagnostic imaging centers in China ... Board of Directors declared a special cash dividend of ... Share ("ADS")) on the Company,s outstanding ordinary shares. The ...
(Date:7/28/2014)... 2014 OmPrompt gab ... £ investiert hat, um die weltweite Nachfrage ... und Logistikbranche zu erfüllen. Albion wird Teil ... http://photos.prnewswire.com/prnh/20140728/697982 ) In ... beschleunigtes Wachstum mit Investitionen in seine Plattform, ...
Breaking Medicine Technology:TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 2TNI BioTech, Inc., Files Definitive Proxy Materials; Mails Letter Urging Shareholders to Vote the Proxy Card 3Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2
(Date:7/28/2014)... (PRWEB) July 28, 2014 With California ... it is welcome news that a fire blanket ... current protection is under development by SunSeeker Enterprises, Inc. ... to protect spacecraft from the extreme heat of re-entry ... both firefighters and homes. , “Our firefighters routinely lay ...
(Date:7/28/2014)... bumping" transmits significantly fewer bacteria than either handshaking ... of hand-to-hand contact between patients and clinicians, according ... of the American Journal of Infection Control ... Professionals in Infection Control and Epidemiology (APIC). , ... Environmental, and Rural Sciences at Aberystwyth University in ...
(Date:7/28/2014)... North America Carotenoids & Antioxidants Market report defines and segments ... and forecast of revenue. This market is estimated to grow ... 2018, at a CAGR of 7.1% from 2013 to 2018. ... & Antioxidants Market report to get an idea of the ... segmentation in the market, and is supported by various tables ...
(Date:7/28/2014)... the July, 2014, issue of the Journal ... Medicine researchers, sheds new light on the risks ... in the treatment of localized, early-stage esophageal cancer. ... while more invasive, provided significantly better outcomes with ... than endoscopic resection, which had a 76 percent ...
(Date:7/28/2014)... New York (PRWEB) July 28, 2014 ... edition of “Organic Living” on March 12th, a campaign ... an organic lifestyle. In partnership with industry leader ... over 100 Certified Organic teas, the campaign provides readers ... recent years that continues to propel the industry forward ...
Breaking Medicine News(10 mins):Health News:Revolutionary Fire Blanket Offers Over 200 Percent More Fire Protection to Firefighters and Homes 2Health News:Fist-bumping beats germ-spreading handshake, study reports 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Carotenoids & Antioxidants (Nutraceuticals) Market is Expected to Reach $812.7 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Study helps compare risks of treatments for early esophageal cancer 2Health News:Study helps compare risks of treatments for early esophageal cancer 3Health News:Mediaplanet's "Organic Living" Campaign Raises Awareness About What Nature Invented, With the Help of Partner TEALUX 2
... -- A Wayne State University study published in the January ... that two influential early studies of cellphone use and crash ... cellphones while driving. In this new study, Richard Young, ... Psychiatry and Behavioral Neurosciences in the School of Medicine, examined ...
... HealthDay Reporter , WEDNESDAY, Dec. 14 (HealthDay News) ... may one day also prove useful in combating serious cases ... Journal of Infectious Diseases finds that patients hospitalized with ... a statin, compared with their peers who weren,t taking one ...
... Institute for Operations Research and the Management Sciences (INFORMS) ... Society Frank P. Ramsey Medal to Dr. Don N. ... market leading provider of web-based financial analytics and performance ... health systems to enhance their financial planning, budgeting, and ...
... by some as being a potent stimulant, but the debate ... of expert opinions capture the scope of this ongoing debate ... Caffeine Research , a quarterly peer-reviewed journal from Mary Ann ... www.liebertpub.com/jcr . Led by Journal of Caffeine Research ...
... Lyon has developed an animal model carrying a mutation of the ... can no longer induce the death of the cancer cells. This ... treatment that aims to reactivate the dying of cancer cells. ... in the 11th December 2011 issue of the journal Nature ...
... face a steep learning curve to get used to new ... before new total knee replacement procedures are as safe and ... operations using a new device in a hospital are 48 ... undergoing an operation to fit a prosthesis previously used in ...
Cached Medicine News:Health News:Wayne State study shows early research on cellphone conversations likely overestimated crash risk 2Health News:Could Statins Help Those Hospitalized With Flu? 2Health News:INFORMS presents Ramsey Medal to health care financial analytics executive Don Kleinmuntz 2Health News:A gene that protects against colorectal cancers 2Health News:Patients at risk of knee joint complications when new technology is used 2
The S8 Escape is the economy model of ResMeds S8 series. The S8 Escape is ideal for patients who want the convenience and portability of the S8 models but do not require the added comfort features of...
... REMstar Plus with C-Flex combines ... and the comfort of C-Flex.With ... REMstar Plus with C-Flex offers ... deliver sleep therapy by taking ...
... a display, ramp capabilities and ... has features that make set-up ... meter records the number of ... four hours - giving you ...
REMstar Pro with C-Flex is a combination of the advances from our other products. The difference is the C-Flex waveform which offers a more comfortable way to deliver sleep therapy by taking the work...
Medicine Products: